Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Masimo Corp (MASI)

Masimo Corp (MASI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What to Expect From Danaher Corporation's Q1 2026 Earnings Report

Washington, D.C.-based Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States and internationally. The company has a market cap of $135.3 billion and operates through Biotechnology, Life Sciences, and Diagnostics segments. 

DHR is expected to release its Q1 2026 earnings on Tuesday, Apr. 21, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $1.94 on a diluted basis, up 3.2% from $1.88 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.

Fundamentals

See More
  • Market Capitalization, $K 9,592,783
  • Shares Outstanding, K 53,714
  • Annual Sales, $ 1,527 M
  • Annual Income, $ -151,500 K
  • EBIT $ 310 M
  • EBITDA $ 352 M
  • 60-Month Beta 1.20
  • Price/Sales 6.26
  • Price/Cash Flow 38.32
  • Price/Book 13.26

Options Overview Details

View History
  • Implied Volatility 7.41% (+0.21%)
  • Historical Volatility 5.16%
  • IV Percentile 8%
  • IV Rank 4.05%
  • IV High 69.93% on 04/07/25
  • IV Low 4.76% on 03/05/26
  • Expected Move (DTE 11) 2.00 (1.12%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 712
  • Volume Avg (30-Day) 777
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 18,524
  • Open Int (30-Day) 15,280
  • Expected Range 176.41 to 180.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.41
  • Number of Estimates 4
  • High Estimate $1.49
  • Low Estimate $1.35
  • Prior Year $1.36
  • Growth Rate Est. (year over year) +3.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
175.30 +1.72%
on 03/09/26
179.00 -0.39%
on 03/24/26
+2.89 (+1.65%)
since 03/06/26
3-Month
128.89 +38.34%
on 01/14/26
179.00 -0.39%
on 03/24/26
+41.71 (+30.53%)
since 01/06/26
52-Week
125.94 +41.58%
on 01/05/26
179.00 -0.39%
on 03/24/26
+33.91 (+23.48%)
since 04/04/25

Most Recent Stories

More News
What to Expect From Danaher Corporation's Q1 2026 Earnings Report

Danaher Corporation is approaching its first-quarter earnings release in a few weeks, and Wall Street is forecasting a low single-digit percentage rise in earnings.

XLV : 146.12 (-0.47%)
$SPX : 6,601.17 (+0.28%)
MASI : 178.44 (-0.08%)
DHR : 191.57 (+0.24%)
3 Small-Cap Stocks Walking a Fine Line

3 Small-Cap Stocks Walking a Fine Line

ASAN : 6.22 (-2.35%)
MASI : 178.44 (-0.08%)
COLB : 27.80 (+0.25%)
2 Unprofitable Stocks to Research Further and 1 Facing Headwinds

2 Unprofitable Stocks to Research Further and 1 Facing Headwinds

MASI : 178.44 (-0.08%)
NET : 208.85 (-1.34%)
SNAP : 4.71 (+1.73%)
1 Healthcare Stock Worth Investigating and 2 That Underwhelm

1 Healthcare Stock Worth Investigating and 2 That Underwhelm

CI : 274.82 (+1.78%)
MASI : 178.44 (-0.08%)
XRAY : 11.49 (-1.20%)
These 3 Defensive Stocks Just Hit 52-Week Highs — Should You Lock In Gains?

High PEG ratios indicate that many defensive stocks in health care and consumer staples trade at stretched valuations. With earnings growth lagging price momentum, three stand out as candidates for profit-taking...

DAR : 63.55 (-1.70%)
VLO : 244.50 (+0.17%)
MASI : 178.44 (-0.08%)
ETON : 25.10 (+0.44%)
DHR : 191.57 (+0.24%)
1 Momentum Stock to Target This Week and 2 Facing Headwinds

1 Momentum Stock to Target This Week and 2 Facing Headwinds

MO : 65.82 (+0.09%)
BG : 128.11 (-1.01%)
MASI : 178.44 (-0.08%)
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACLX : 114.73 (-0.03%)
MASI : 178.44 (-0.08%)
FONR : 18.59 (unch)
Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACLX : 114.73 (-0.03%)
GLDD : 17.00 (+0.18%)
MASI : 178.44 (-0.08%)
3 Overrated Stocks We Steer Clear Of

3 Overrated Stocks We Steer Clear Of

MASI : 178.44 (-0.08%)
SWBI : 14.69 (-1.14%)
HIMX : 8.93 (+12.61%)
Patient Monitoring Stocks Q3 Recap: Benchmarking Masimo (NASDAQ:MASI)

Patient Monitoring Stocks Q3 Recap: Benchmarking Masimo (NASDAQ:MASI)

MASI : 178.44 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Masimo Corporation develops, manufactures and markets a family of non-invasive monitoring systems. The Company has two segments: Product Revenues, Royalty & Other revenues. Within Product revenues, the company's flagship - Signal Extraction Tecgnology (SET) Pulse Oximetry - is used to monitor blood oxygen...

See More

Key Turning Points

3rd Resistance Point 179.74
2nd Resistance Point 179.20
1st Resistance Point 178.89
Last Price 178.44
1st Support Level 178.04
2nd Support Level 177.50
3rd Support Level 177.19

See More

52-Week High 179.00
Last Price 178.44
Fibonacci 61.8% 158.73
Fibonacci 50% 152.47
Fibonacci 38.2% 146.21
52-Week Low 125.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.